WO2009127666A3 - Vaccination compositions or combinations against cancer - Google Patents

Vaccination compositions or combinations against cancer Download PDF

Info

Publication number
WO2009127666A3
WO2009127666A3 PCT/EP2009/054479 EP2009054479W WO2009127666A3 WO 2009127666 A3 WO2009127666 A3 WO 2009127666A3 EP 2009054479 W EP2009054479 W EP 2009054479W WO 2009127666 A3 WO2009127666 A3 WO 2009127666A3
Authority
WO
WIPO (PCT)
Prior art keywords
against cancer
combinations against
vaccination compositions
methods
responses
Prior art date
Application number
PCT/EP2009/054479
Other languages
French (fr)
Other versions
WO2009127666A2 (en
Inventor
Vincent Brichard
Catherine Marie Ghislaine Gerard
Jamila Louahed
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of WO2009127666A2 publication Critical patent/WO2009127666A2/en
Publication of WO2009127666A3 publication Critical patent/WO2009127666A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Abstract

Vaccine compositions and methods for their use in the stimulation of immune responses in mammals, including humans, are provided. Also provided are methods for the prevention and treatment of cancer. These relate to breaking immune tolerance to selfantigens, inducing CD4+ and CD8+ T-cell responses, and inducing antibody responses in subjects without recourse to complex prime-boost schedules.
PCT/EP2009/054479 2008-04-15 2009-04-15 Method and compositions WO2009127666A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4509008P 2008-04-15 2008-04-15
US61/045,090 2008-04-15

Publications (2)

Publication Number Publication Date
WO2009127666A2 WO2009127666A2 (en) 2009-10-22
WO2009127666A3 true WO2009127666A3 (en) 2010-01-07

Family

ID=41110506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054479 WO2009127666A2 (en) 2008-04-15 2009-04-15 Method and compositions

Country Status (1)

Country Link
WO (1) WO2009127666A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750110A (en) * 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
WO1998056919A2 (en) * 1997-06-09 1998-12-17 Oxxon Pharmaccines Limited Methods and reagents for vaccination which generate a cd8 t cell immune response
WO2005035779A2 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc Method
WO2005105139A2 (en) * 2004-05-04 2005-11-10 Glaxosmithkline Biologicals S.A. Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750110A (en) * 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
WO1998056919A2 (en) * 1997-06-09 1998-12-17 Oxxon Pharmaccines Limited Methods and reagents for vaccination which generate a cd8 t cell immune response
WO2005035779A2 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc Method
WO2005105139A2 (en) * 2004-05-04 2005-11-10 Glaxosmithkline Biologicals S.A. Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANGARI D S ET AL: "Development of nonhuman adenoviruses as vaccine vectors", VACCINE, BUTTERWORTH SCIENTIFIC, vol. 24, no. 7, 13 February 2006 (2006-02-13), GUILDFORD, GB, pages 849 - 862, XP025151912, ISSN: 0264-410X, [retrieved on 20060213] *
HUTCHINGS CLAIRE L ET AL: "Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge", INFECTION AND IMMUNITY, vol. 75, no. 12, December 2007 (2007-12-01), pages 5819 - 5826, XP002549178, ISSN: 0019-9567 *
KWISSA M ET AL: "Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response", JOURNAL OF MOLECULAR MEDICINE, vol. 81, no. 8, 16 July 2003 (2003-07-16), SPRINGER VERLAG, DE, pages 502 - 510, XP002404711, ISSN: 0946-2716 *

Also Published As

Publication number Publication date
WO2009127666A2 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
CA2759013C (en) Combination immunotherapy compositions against cancer and methods
PH12014501835A1 (en) Novel adjuvant compositions
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
CN106661570A8 (en) By the sleeping beauty transposon stand preparation engineering T cell that coupling is selected with amethopterin
EA201400625A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION
MX2017006408A (en) Engineered gamma delta t-cells.
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
MX2013011740A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses.
WO2008116078A3 (en) Stimulation of an immune response by cationic lipids
WO2011143656A3 (en) Compositions and methods of identifying tumor specific neoantigens
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
IN2012DN01920A (en)
WO2012149265A3 (en) Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
MX2009008918A (en) Activation of human antigen-presenting cells through clec-6.
EP3734281A3 (en) Therapeutic and diagnostic methods relating to cancer stem cells
BR112013012555A2 (en) Immunogenic peptides for use in the prevention and / or treatment of infectious diseases, autoimmune diseases, immune responses to allopaths, allergic diseases, tumors, graft rejection, and immune responses against viral vectors used for gene therapy or gene vaccination.
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2012116225A3 (en) Muc1 based glycolipopeptide vaccine with adjuvant
UA111738C2 (en) METHOD OF ACTIVE CANCER IMMUNOTHERAPY BY CANCER BY USING TUMOR CELLS DESTROYED BY HIGH HYDROSTATIC TISCODINE
WO2009135199A3 (en) Vaccine compositions and methods
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2009127666A3 (en) Vaccination compositions or combinations against cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09732739

Country of ref document: EP

Kind code of ref document: A2